Results suggest research is closer to making recombinant factor VIIa work ...

Results from the largest-ever clinical trial of its kind found administering a synthetic protein can reduce bleeding and ...

Global phase 3 OCEANIC-STROKE randomized 12,327 patients to asundexian 50 mg daily vs placebo on background antiplatelets, with follow-up to 31 months. Treatment effects were consistent across TOAST ...

The factor XIa inhibitor asundexian reduced recurrent ischemic stroke without increasing major or minor bleeding in patients ...

NEW ORLEANS, LA—Adding the factor XIa inhibitor asundexian (Bayer) to antiplatelet therapy tops antiplatelet therapy alone ...

Clinical trial results indicate a protein, rFVIIa, may benefit certain stroke patients when administered quickly, with a focus on acute intracerebral hemorrhage treatments.

Though recombinant factor VIIa didn’t improve outcomes overall, treating very early and in those with a spot sign on CT may help.

Please provide your email address to receive an email when new articles are posted on . Study analyzed 587 adults with intracranial hemorrhage before and after artificial intelligence algorithm ...

Intracranial hemorrhage (ICH) refers to acute bleeding inside your skull or brain. It’s a life-threatening emergency. You should go to the emergency room right away or call 911 if you think you or ...

For patients with noncardioembolic ischemic stroke or high-risk transient ischemic attack, asundexian, a factor XIa inhibitor ...